# LUMMICAR STUDY 1

Source: https://onco.cc/trials/lummicar-1/  
OnCo record `lummicar-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Chinese trial behind zevor-cel's approval for multiple myeloma, showing deep and lasting responses with a fully human BCMA CAR-T.

## Summary

Phase 1/2 single-arm study at Chinese centres; the phase 2 report (Experimental Hematology and Oncology 2025) described high overall and complete response rates, deep minimal residual disease negativity and predominantly low-grade cytokine release syndrome. Basis of NMPA approval in February 2024. A parallel North American study (LUMMICAR STUDY 2) was run by CARsgen before it refocused on China.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Registry id: NCT03975907
- Phase: 1/2
- Setting: Relapsed or refractory multiple myeloma after three or more lines, China: single-arm study of zevorcabtagene autoleucel (CT053)
- Sponsor: CARsgen Therapeutics
- Enrolled: 102
- Outcomes: Objective response rate (independent review committee): Zevorcabtagene autoleucel 92.2%; Stringent complete response: Zevorcabtagene autoleucel 68.6%; Cytokine release syndrome, any grade: Zevorcabtagene autoleucel 90.2%
- Replication: Single-arm phase 2 at 23 Chinese centres (patients with prior BCMA-directed or CAR-T therapy excluded). Consistent with FUMANBA-1 (eque-cel, ORR 96%) and with the North American LUMMICAR STUDY 2 dose-finding cohort; no randomised trial against standard regimens.

## Sources

- ClinicalTrials.gov NCT03975907: https://clinicaltrials.gov/study/NCT03975907
- Exp Hematol Oncol 2025: https://doi.org/10.1186/s40164-025-00710-y

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- drugs: [Zevorcabtagene autoleucel](https://onco.cc/drugs/zevorcabtagene-autoleucel/)
- companies: [CARsgen Therapeutics](https://onco.cc/companies/carsgen/)
- key papers: [Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma](https://onco.cc/key-papers/paper-chen-exp-hematol-oncol/)

---
JSON: https://onco.cc/api/v1/entities/lummicar-1.json